Cargando…

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

BACKGROUND: Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer (mCRC). Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials compared to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricci, Vincenzo, Granetto, Cristina, Falletta, Antonella, Paccagnella, Matteo, Abbona, Andrea, Fea, Elena, Fabozzi, Teresa, Lo Nigro, Cristiana, Merlano, Marco Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081116/ https://www.ncbi.nlm.nih.gov/pubmed/32206180 http://dx.doi.org/10.4251/wjgo.v12.i3.301

Ejemplares similares

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib
por: Abbona, Andrea, et al.
Publicado: (2023)

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy
por: Merlano, Marco Carlo, et al.
Publicado: (2021)

Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study
por: Garrone, Ornella, et al.
Publicado: (2020)

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
por: Paccagnella, Matteo, et al.
Publicado: (2022)

Heterogeneity of colon cancer: from bench to bedside
por: Merlano, Marco C, et al.
Publicado: (2017)

The Role of Cytokinome in the HNSCC Tumor Microenvironment: A Narrative Review and Our Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review
por: Denaro, Nerina, et al.
Publicado: (2021)

Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment
por: Merlano, Marco Carlo, et al.
Publicado: (2023)

Long noncoding RNAs as regulators of cancer immunity
por: Denaro, Nerina, et al.
Publicado: (2018)

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
por: Denaro, Nerina, et al.
Publicado: (2021)

How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review
por: Merlano, Marco Carlo, et al.
Publicado: (2022)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness
por: Xu, Yu-Jie, et al.
Publicado: (2022)

Head and neck cancer: improving outcomes with a multidisciplinary approach
por: Lo Nigro, Cristiana, et al.
Publicado: (2017)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
por: Denaro, Nerina, et al.
Publicado: (2013)

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
por: Adhoute, Xavier, et al.
Publicado: (2022)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma
por: Li, Ning, et al.
Publicado: (2022)

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
por: Belli, Valentina, et al.
Publicado: (2017)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
por: Nannini, Margherita, et al.
Publicado: (2017)

Knowing the tumour microenvironment to optimise immunotherapy
por: MERLANO, M.C., et al.
Publicado: (2019)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
por: Khan, Khurum, et al.
Publicado: (2018)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
por: Pastor, Brice, et al.
Publicado: (2021)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer
por: Ebinç, Senar, et al.
Publicado: (2022)

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery
por: Goio, Elisabetta, et al.
Publicado: (2020)

PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer
por: Raimondi, Lucrezia, et al.
Publicado: (2020)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
por: Khan, Gazala, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vit1g7r374snf1q1ee0smvj9ed